Opinion|Videos|December 25, 2024
Hypertension in Pregnancy and Women
Key Takeaways
- Difficult-to-treat hypertension involves uncontrolled blood pressure despite using three or more antihypertensive medications, including a diuretic.
- It is distinct from resistant hypertension, which is more common and may not include a diuretic in treatment.
A panelist discusses how hypertensive disorders during pregnancy remain a leading cause of maternal mortality worldwide, affecting 5-10% of pregnancies and requiring careful monitoring, early detection, and appropriate medical management to protect both mother and baby.
Advertisement
Episodes in this series
Video content above is prompted by the following:
How does aprocitentan address the current challenges associated with hypertension treatment (eg, improved efficacy: systolic/diastolic control 24 hours a day, improved safety regarding hyperkalemia/hypotension, and reduced drug-drug interactions)?
Advertisement
Related to this article
A new analysis of 4 major trials has revealed the association between lower SBP and higher TTR and the risk of recurrent stroke after intracerebral hemorrhage.
An NHANES analysis finds 82.3% of 9.1 million US adults eligible for kidney-protective GLP-1 RA therapy are unaware of their CKD, with no improvement over a decade.
Long-term extension data show iptacopan held a −3.49 mL/min/1.73 m² per year eGFR slope over 48 months, with benefit emerging after patients switched from placebo.
Reena Mehra, MD, discusses a post hoc analysis in which AD109 reduced AHI4 by 59.6% in postmenopausal women vs 44.0% in non-menopausal participants.
Final 96-week phase 1b data show sustained UPCR reduction and stable eGFR about 1.5 years after the last mezagitamab dose, with no serious adverse events.
Final VISIONARY data show sibeprenlimab held eGFR steady over 24 months, with a 4.5 mL/min/1.73 m² per year slope advantage and fewer kidney outcome events vs placebo.
Jonathan Barratt, PhD, FRCP, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack final ORIGIN 3 eGFR data for atacicept in IgAN.
In phase 3 INTREPID, lutikizumab beat placebo on HiSCR75 at week 16 and met all 8 ranked secondary end points in moderate to severe HS.
Advertisement
Advertisement
Trending on HCPLive
1
Tozorakimab Improves Daily Respiratory Symptoms in COPD: OBERON, TITANIA
2
Tozorakimab Sustains COPD Exacerbation Benefit to 2 Years: Henrik Watz, MD
3
AAD's New HS Guidelines Flag 'Step Therapy' as Top Barrier to Care
4
Depemokimab Year 1 Remission Linked to Better Year 2 Asthma Outcomes
5